426 related articles for article (PubMed ID: 31268127)
1. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.
Marchiò C; Scaltriti M; Ladanyi M; Iafrate AJ; Bibeau F; Dietel M; Hechtman JF; Troiani T; López-Rios F; Douillard JY; Andrè F; Reis-Filho JS
Ann Oncol; 2019 Sep; 30(9):1417-1427. PubMed ID: 31268127
[TBL] [Abstract][Full Text] [Related]
2. Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population.
Zhao R; Yao F; Xiang C; Zhao J; Shang Z; Guo L; Ding W; Ma S; Yu A; Shao J; Zhu L; Han Y
J Pathol Clin Res; 2021 Jul; 7(4):375-384. PubMed ID: 33768710
[TBL] [Abstract][Full Text] [Related]
3. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
[TBL] [Abstract][Full Text] [Related]
4. Identifying patients with NTRK fusion cancer.
Solomon JP; Benayed R; Hechtman JF; Ladanyi M
Ann Oncol; 2019 Nov; 30 Suppl 8():viii16-viii22. PubMed ID: 32223934
[TBL] [Abstract][Full Text] [Related]
5. The oncogenic roles of NTRK fusions and methods of molecular diagnosis.
Aref-Eshghi E; Lin F; Li MM; Zhong Y
Cancer Genet; 2021 Nov; 258-259():110-119. PubMed ID: 34710798
[TBL] [Abstract][Full Text] [Related]
6. TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening.
Albert CM; Davis JL; Federman N; Casanova M; Laetsch TW
J Clin Oncol; 2019 Feb; 37(6):513-524. PubMed ID: 30592640
[TBL] [Abstract][Full Text] [Related]
7. NTRK Gene Fusion Detection in Atypical Spitz Tumors.
Cappellesso R; Nozzoli F; Zito Marino F; Simi S; Castiglione F; De Giorgi V; Cota C; Senetta R; Scognamiglio G; Anniciello AM; Cesinaro AM; Mandalà M; Gianatti A; Valente MG; Valeri B; Sementa AR; Ricci C; Corti B; Roviello G; Dei Tos AP; Franco R; Massi D
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830218
[TBL] [Abstract][Full Text] [Related]
8. Identifying patients with NTRK fusion cancer.
Solomon JP; Benayed R; Hechtman JF; Ladanyi M
Ann Oncol; 2019 Nov; 30(Suppl_8):viii16-viii22. PubMed ID: 31738428
[TBL] [Abstract][Full Text] [Related]
9. NTRK fusions and Trk proteins: what are they and how to test for them.
Weiss LM; Funari VA
Hum Pathol; 2021 Jun; 112():59-69. PubMed ID: 33794242
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib.
Rudzinski ER; Hechtman J; Roy-Chowdhuri S; Rudolph M; Lockwood CM; Silvertown J; Wierzbinska J; Shen K; Norenberg R; Nogai H; Hong DS; Drilon A; Laetsch TW
Cancer Genet; 2022 Jan; 260-261():46-52. PubMed ID: 34929613
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of cancers with NTRK gene fusions.
Gatalica Z; Xiu J; Swensen J; Vranic S
Mod Pathol; 2019 Jan; 32(1):147-153. PubMed ID: 30171197
[TBL] [Abstract][Full Text] [Related]
12. Testing algorithm for identification of patients with TRK fusion cancer.
Penault-Llorca F; Rudzinski ER; Sepulveda AR
J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837
[TBL] [Abstract][Full Text] [Related]
13. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
[TBL] [Abstract][Full Text] [Related]
14. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing.
Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ
Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853
[TBL] [Abstract][Full Text] [Related]
15. Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours.
Garrido P; Hladun R; de Álava E; Álvarez R; Bautista F; López-Ríos F; Colomer R; Rojo F
Clin Transl Oncol; 2021 Aug; 23(8):1529-1541. PubMed ID: 33620682
[TBL] [Abstract][Full Text] [Related]
16. NTRK-Rearranged soft tissue neoplasms: A review of evolving diagnostic entities and algorithmic detection methods.
Surrey LF; Davis JL
Cancer Genet; 2022 Jan; 260-261():6-13. PubMed ID: 34794069
[TBL] [Abstract][Full Text] [Related]
17.
Gambella A; Senetta R; Collemi G; Vallero SG; Monticelli M; Cofano F; Zeppa P; Garbossa D; Pellerino A; Rudà R; Soffietti R; Fagioli F; Papotti M; Cassoni P; Bertero L
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979374
[TBL] [Abstract][Full Text] [Related]
18. Elaboration of NTRK-rearranged colorectal cancer: Integration of immunoreactivity pattern, cytogenetic identity, and rearrangement variant.
Wu S; Liu Y; Shi X; Zhou W; Zeng X
Dig Liver Dis; 2023 Dec; 55(12):1757-1764. PubMed ID: 37142453
[TBL] [Abstract][Full Text] [Related]
19. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?].
Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T
Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719
[TBL] [Abstract][Full Text] [Related]
20. NTRK fusion-positive cancers and TRK inhibitor therapy.
Cocco E; Scaltriti M; Drilon A
Nat Rev Clin Oncol; 2018 Dec; 15(12):731-747. PubMed ID: 30333516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
